Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Hydrocortisone is a short-acting synthetic glucocorticoid with both mineralocorticoid and glucocorticoid activity. In acute asthma, systemic corticosteroids are used to reduce inflammation, reverse beta-agonist resistance, and prevent relapse. IV administration is typically reserved for patients unable to tolerate oral (PO) medications.
## Primary Indications
* Management of acute, severe asthma exacerbations unresponsive to initial intensive bronchodilator therapy.
* Patients unable to swallow or those with persistent vomiting.
## Adult Dosing
* **Dose:** 100 mg IV every 6 to 8 hours.
* **Note:** Oral prednisone/prednisolone is preferred over IV hydrocortisone if the patient can tolerate PO intake. Equipotent oral doses are as effective; there is no evidence that IV administration provides faster clinical improvement.
## Pediatric Dosing
* **Dose:** 5–10 mg/kg/dose IV every 6 hours (Max: 100 mg per dose).
* **Note:** Pediatric guidelines strongly favor oral corticosteroids (e.g., prednisolone) as first-line therapy for acute exacerbations.
## Dose Adjustments
* **Hepatic impairment:** May require dose reduction or closer monitoring due to decreased drug metabolism.
* **Renal impairment:** No routine dosage adjustment required, though patients are at higher risk for fluid/electrolyte imbalances.
## Contraindications
* Known hypersensitivity to hydrocortisone or any component of the formulation.
* Systemic fungal infections.
* Administration of live or live-attenuated vaccines (in patients receiving immunosuppressive doses).
## Adverse Effects
* **Common:** Hyperglycemia, hypertension, fluid retention, hypokalemia, and insomnia.
* **Serious:** Secondary adrenal insufficiency (with prolonged use), masked signs of infection, psychiatric disturbances, gastrointestinal ulceration, and posterior subcapsular cataracts.
## Key Drug Interactions
* **CYP3A4 inducers (e.g., phenytoin, rifampin):** May decrease hydrocortisone efficacy.
* **CYP3A4 inhibitors (e.g., ritonavir, ketoconazole):** May increase hydrocortisone serum concentrations.
* **NSAIDs:** Increased risk of gastrointestinal ulceration/bleeding.
* **Diuretics:** Increased risk of hypokalemia.
## Monitoring
* **Efficacy:** Respiratory rate, oxygen saturation, physical assessment (wheezing, accessory muscle use), and peak expiratory flow.
* **Safety:** Blood glucose (especially in diabetics), blood pressure, electrolyte status (potassium), and signs of infection.
## Clinical Pearls
* **Transition to PO:** Convert to oral corticosteroids as soon as the patient is able to tolerate them.
* **Tapering:** Short courses (e.g., 3–10 days) for acute asthma exacerbations usually do not require a taper.
* **Formulation:** Ensure the correct salt is used; hydrocortisone sodium succinate is the standard for IV injection.
* **Local Protocols:** Dosing and transition strategies vary significantly by institution; always consult local clinical pathways or institutional guidelines.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and clinical protocols may vary significantly. Always verify the most current prescribing information, institutional guidelines, and drug compatibility data before administration.
